{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:21:28Z","timestamp":1788877288253,"version":"build-2803163510"},"reference-count":19,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Avatar Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Introduction: Sodium glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide 1 receptor (GLP-1) agonists are recommended for patients with type two diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) to reduce cardiovascular-related mortality. The objective of this study was to evaluate a telehealth targeted medication review (TMR) program to identify patients for uptake of these evidence-based medications. Methods: This was an observational descriptive study of a TMR program for Medicare-enrolled, Medication Therapy Management-eligible patients in one insurance plan. Prescription claims and patient interviews identified individuals who would benefit from SGLT-2 inhibitors or GLP-1 agonists. Facsimiles were sent to providers of patients with educational information about the targeted medications. Descriptive statistics described characteristics and proportion of patients prescribed targeted medications after 120 days. Bivariate statistical tests evaluated associations between age, sex, number of medications, number of providers, and poverty level with adoption of targeted medications. Results: A total of 1106 of 1127 had a facsimile sent to their provider after a conversation with the patient. Among patients with a provider facsimile, 69 (6%) patients filled a prescription for a targeted medication after 120 days. There was a significant difference in age between individuals who started a targeted medication (67 \u00b1 10 years) compared with patients who did not (71 \u00b1 10 years) (p = 0.001). Conclusions: A TMR efficiently identified patients with T2D and ASCVD or HF who would benefit from evidence-based medications. Although younger patients were more likely to receive these medications, the overall uptake of these medications within four months of the intervention was lower than expected.<\/jats:p>","DOI":"10.3390\/ijerph20043613","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T03:29:06Z","timestamp":1676863746000},"page":"3613","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Telehealth Intervention to Improve Uptake of Evidence-Based Medications among Patients with Type 2 Diabetes and Heart Failure or Cardiovascular Disease"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-9413","authenticated-orcid":false,"given":"Armando","family":"Silva-Almod\u00f3var","sequence":"first","affiliation":[{"name":"Institute of Therapeutic Innovations and Outcomes (ITIO), College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milap C.","family":"Nahata","sequence":"additional","affiliation":[{"name":"College of Medicine, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1093\/eurjpc\/zwaa073","article-title":"Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC\/EASD: Data from a large Mediterranean population","volume":"28","author":"Mauricio","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional, Practice Committee 9 (2021). Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes\u20142022. Diabetes Care, 45, S125\u2013S143.","DOI":"10.2337\/dc22-S009"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2035792","DOI":"10.1001\/jamanetworkopen.2020.35792","article-title":"Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019","volume":"4","author":"McCoy","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc21-1815","article-title":"Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veteran\u2019s Affairs","volume":"45","author":"Mahtta","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2337\/dc21-1178","article-title":"Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry","volume":"45","author":"Essien","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e023811","DOI":"10.1161\/JAHA.121.023811","article-title":"National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"109036","DOI":"10.1016\/j.diabres.2021.109036","article-title":"Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists","volume":"180","author":"Milder","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Singhal, P., Liu, G., Nadeswaran, P., Miller, S., Motiani, M., Latz, M., Wee, C.P., and Van Herle, H. (2022). Improving Utilization Of Sglt2 Inhibitors Via Education At A Single-Center Academic Safety-Net Hospital. J. Am. Coll. Cardiol., 79.","DOI":"10.1016\/S0735-1097(22)02531-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2215\/CJN.02690320","article-title":"Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease","volume":"15","author":"Li","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_10","unstructured":"Contract Year 2023 Medication Therapy Management Program Information and Submission Instructions (2022, December 08). Centers for Medicare and Medicaid Services Web Site, Available online: https:\/\/www.cms.gov\/files\/document\/memo-contract-year-2023-medication-therapy-management-mtm-program-submission-v041522.pdf."},{"key":"ref_11","unstructured":"(2022, December 08). Who\u2019s Eligible for Medicare? U.S. Department of Health & Human Services Web Site, Available online: https:\/\/www.hhs.gov\/answers\/medicare-and-medicaid\/who-is-eligible-for-medicare\/index.html."},{"key":"ref_12","unstructured":"(2022, December 08). Explore Census Data. United States Census Bureau Web Site, Available online: https:\/\/data.census.gov\/cedsci\/."},{"key":"ref_13","unstructured":"United States Census Bureau (2022, December 08). Geographic Levels. United States Census Bureau Web Site, Available online: https:\/\/www.census.gov\/programs-surveys\/economic-census\/guidance-geographies\/levels.html#par_textimage_34."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12626","article-title":"Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/2633559X20968283","article-title":"Overcoming Therapeutic Inertia in the Age of Advanced Diabetes Medication Therapy and Technology","volume":"9","author":"Grossman","year":"2021","journal-title":"ADCES Pract."},{"key":"ref_16","unstructured":"(2022, December 13). Copayment\/Coinsurance in Drug Plans. Centers for Medicare and Medicaid Services Web Site, Available online: https:\/\/www.medicare.gov\/drug-coverage-part-d\/costs-for-medicare-drug-coverage\/copaymentcoinsurance-in-drug-plans."},{"key":"ref_17","unstructured":"(2022, December 13). Ways to Get Help with Prescription Costs. Centers for Medicare and Medicaid Services Web Site, Available online: https:\/\/www.medicare.gov\/drug-coverage-part-d\/costs-for-medicare-drug-coverage\/costs-in-the-coverage-gap\/5-ways-to-get-help-with-prescription-costs."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2020969","DOI":"10.1001\/jamanetworkopen.2020.20969","article-title":"Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program","volume":"3","author":"Luo","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2337\/dc21-1757","article-title":"Cost-Related Medication Nonadherence in Adults With Diabetes in the United States: The National Health Interview Survey 2013\u20132018","volume":"45","author":"Taha","year":"2022","journal-title":"Diabetes Care"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/4\/3613\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:40:09Z","timestamp":1760121609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/4\/3613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijerph20043613"],"URL":"https:\/\/doi.org\/10.3390\/ijerph20043613","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}